Cartesian Therapeutics FY2023 net loss $219.7M; cash runway into 2H26

Cartesian Therapeutics, Inc.

Pro forma cash $118.3M as of Dec 31, 2023, expected to fund operations into 2H26.
Net loss of $219.7M ($1.66/share) vs net income of $35.4M ($0.24/share) in FY2022.
R&D expenses $71.8M, G&A $40.6M; G&A rose $16.7M on merger costs.
Topline Phase 2b data for Descartes-08 in MG expected mid-2024; Phase 2 SLE study to start 1H24.
Special stockholder meeting March 27, 2024 to vote on preferred conversion and 1:20-1:30 reverse stock split.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Cartesian Therapeutics, Inc. reported financial results for the full year ended December 31, 2023.

Period: the full year ended December 31, 2023
Result: reported results

Exact text from the filing

Cartesian Therapeutics, Inc. announced its financial results for the year ended December 31, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Cartesian Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001453687-24-000035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.